


DOCUMENT INTENDED EXCLUSIVELY FOR QUALIFIED PROFESSIONAL COUNTERPARTIES

Deep Knowledge Group (DKG) is a data science-driven financial corporation focusing on knowledge aggregation and considering the Longevity Industry as a major priority. The company combines commercial and non-profit organizations under its umbrella, active on many fronts in the realm of DeepTech and Frontier Technologies, ranging from scientific research to investment, entrepreneurship, analytics, media, philanthropy, and more.

DKG considers Longevity Biomarkers as a strategic core engine for its Longevity activities and as a major catalyst for the development of the whole Longevity Industry. According to the latest report produced by subsidiaries of DKG, this industry consist of 300 companies, 495 investors, 235 R&D organizations and 7 non-profits. Moreover, biomarker panels can be used as tangible, validated tools to evaluate and benchmark Longevity companies, conducting data-driven evidence-based due diligence. To take advantage of all these opportunities, DKG established a Quant Biomarkers company in Switzerland in November 2021.



Read More: www.longevity.international/biomarkers

Deep Knowledge Group and Aging Analytics are transferring all biomarker-related assets to develop Quant Biomarkers Company.

Quant Biomarkers Plans and Goals for 2022


 <p>Establish Longevity Biomarkers R&D Facility</p>	<p>Internal team development, establishing of advanced Longevity Biomarkers R&D facility</p>	 <p>Integration with Advanced InsurTech IT-platform</p>	<p>Develop system for Longevity precise personalised diagnostics based on Longevity biomarkers assessment and integrate it with Advanced InsurTech IT-Platform</p>	 <p>Become Global Market Leader</p>	<p>Becoming undoubtedly a global market leader in structuring financial products tied to Longevity Biomarkers</p>
--	--	---	--	---	---

Further, Quant Biomarkers Company will be both an incubator, accelerator, and investment vehicle operating in the Longevity Biomarkers sector, acquiring the most prospective startups, teams, and R&D facilities in the industry for the development of Longevity financial products and services.


Quant Biomarkers Office Location

-  Front Office in Basel, Switzerland
-  Back Office Dedicated to Biomarker R&D in Kyiv, Ukraine
-  Financial Structuring Office in London
-  Back Office Dedicated to IT-development in Berlin, Germany





Quant Biomarkers Roadmap 2022



The scope of our activities within the Longevity Biomarkers Industry is not limited to creation of the uniquely engineered Longevity-tied financial instruments. We set a goal to identify and assess various financial solutions that would be based on diseases-related biomarkers as well.

Quant Biomarkers Services

Market Assessment

- Market Dynamics Analysis
- Market Forecasting
- Business Intelligence Analysis of the Companies
- Due Diligence
- Valuation

Financial Services

- Longevity-tied Financial Instruments Creation
- Longevity and Mortality Indices Development
- Hedging Optimization for Insurance and Reinsurance Companies
- Risk Optimization for Governmental and Private Pension Funds


Longevity Biomarker Big Data Analytics Dashboard

One of the technical solutions developed by the company is Longevity Biomarkers-based Big Data Analytics Dashboard. Deep Knowledge Group's value-proposition will be delivered through the Biomarkers-based AI-fueled models applicable for computational risks assessment, general risk management, and de-risking practices.

Longevity Risk Modelling

As a specific example of the services provided via the Dashboard is Longevity Risk Modelling. This service enables clients to manage Longevity Risk more flexibly compared to currently available products such as life annuities.

Our AI-driven big data analytics tools support the release of longevity derivatives, which reduces the longevity risk substantially for life annuities.



Automated Data-driven Due Diligence

Using sophisticated quantitative analytical frameworks, we identify and provide recommendations on the most promising startups, most undervalued or overvalued companies. Enhanced due diligence includes deep ratios' analysis of scientific and technological strength, assessment of management team, analysis of marketing, IP and other pertinent metrics to strengthen and automate the due diligence process.

